AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10523477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 90 mg/day
Number of subjects: 201
Study 10523477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS mean dose of 52.3 mg/day during one-year open label phase
Number of subjects: 201
Study 10523477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 8748432 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-988 (300 mg/day, thrice daily)
Number of subjects: 88
Study 8748432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 8748432 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-988
Number of subjects: 88
Study 8173699 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril on low salt intake
Number of subjects: 9
Study 8173699 — intervention group
Group type: COMPARATOR
Intervention: cilazapril on high salt intake
Number of subjects: 9
Study 8173699 — intervention group
Group type: COMPARATOR
Intervention: dihydralazine on low salt intake
Number of subjects: 9
Study 8173699 — intervention group
Group type: COMPARATOR
Intervention: dihydralazine on high salt intake
Number of subjects: 9
Study 3885441 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral analgesia with paracetamol 320 mg, caffeine 32 mg, codeine phosphate 8 mg, and meprobamate 150 mg (Stopayne)
Number of subjects: 0
Study 3885441 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral analgesia with dipyrone 500 mg, pitofenone hydrochloride 5 mg, and fenpiverinium bromide 0.1 mg (Baralgan HS)
Number of subjects: 0
Study 3885441 — intervention group
Group type: COMPARATOR
Intervention: Parenteral administration of pethidine 100 mg
Number of subjects: 0
Study 3885441 — intervention group
Group type: COMPARATOR
Intervention: Parenteral administration of dipyrone 2500 mg
Number of subjects: 0
Study 31887803 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase injection (5000 IU)
Number of subjects: 148
Study 31887803 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline injection)
Number of subjects: 148
Study 29795544 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (manual pressure on the lateral heel)
Number of subjects: 28
Study 29795544 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation (manual pressure on the lateral ankle)
Number of subjects: 28
Study 29795544 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 28
Study 29795544 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation
Number of subjects: 28
Study 27591953 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vaccine (7.5 mcg HA)
Number of subjects: 75
Study 27591953 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaccine (15 mcg HA)
Number of subjects: 75
Study 27591953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 24289244 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm Q-switched Nd:YAG laser plus chemical peeling with Jessner's solution
Number of subjects: 52
Study 24289244 — intervention group
Group type: COMPARATOR
Intervention: 1064-nm Q-switched Nd:YAG laser plus chemical peeling with placebo
Number of subjects: 52
Study 24289244 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 52
Study 22071673 — intervention group
Group type: COMPARATOR
Intervention: Corneal sensitivity measurement in PED and corneal erosion groups
Number of subjects: 99
Study 22071673 — intervention group
Group type: COMPARATOR
Intervention: Schirmer test values in SPK group
Number of subjects: 99
Study 19892995 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of pessimism (low pessimism level)
Number of subjects: 23216
Study 18198203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led secondary prevention clinics
Number of subjects: 1343
Study 18198203 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1343
Study 16096831 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg once daily (q.d.)
Number of subjects: 76
Study 16096831 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 30 mg once daily (q.d.)
Number of subjects: 76
Study 16096831 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg three times daily (t.i.d.)
Number of subjects: 76
Study 16096831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 12466341 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg
Number of subjects: 89
Study 12466341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 10603716 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical detection using LAM antibody
Number of subjects: 13
Study 10603716 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical detection using PGL-1, 30 kD and 65 kD antibodies
Number of subjects: 13
Study 10603716 — intervention group
Group type: COMPARATOR
Intervention: Immunohistochemical detection in bacteriologically negative tissue
Number of subjects: 13
Study 10603716 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical detection of protein antigens
Number of subjects: 13
Study 7794078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management
Number of subjects: 136
Study 7794078 — intervention group
Group type: COMPARATOR
Intervention: Control group (operated patients)
Number of subjects: 136
Study 2041036 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine 5 mg ER formulation
Number of subjects: 102
Study 2041036 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 102
Study 6992910 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene) 200 mg t.d.s. for 6 months
Number of subjects: 0
Study 6992910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6992910 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene)
Number of subjects: 0
Study 31109190 — intervention group
Group type: EXPERIMENTAL
Intervention: macitentan 10 mg
Number of subjects: 734
Study 31109190 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 734
Study 28728583 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives up to £400 for smoking cessation
Number of subjects: 93
Study 28728583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 93
Study 26107684 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate Chewable D3 tablet (thrice daily)
Number of subjects: 198
Study 26107684 — intervention group
Group type: COMPARATOR
Intervention: MESE exercise (thrice daily, 7 repetitions per time for 12 months)
Number of subjects: 198
Study 26107684 — intervention group
Group type: COMPARATOR
Intervention: MESE exercise + Calcium Carbonate Chewable D3 tablet (thrice daily for 12 months)
Number of subjects: 198
Study 26107684 — intervention group
Group type: EXPERIMENTAL
Intervention: MESE exercise
Number of subjects: 198
Study 26107684 — intervention group
Group type: EXPERIMENTAL
Intervention: MESE exercise + Calcium Carbonate Chewable D3 tablet
Number of subjects: 198
Study 24565122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide (50% O2-N2O mixture)
Number of subjects: 40
Study 24565122 — intervention group
Group type: COMPARATOR
Intervention: Control (50% O-air mixture)
Number of subjects: 40
Study 21040197 — intervention group
Group type: EXPERIMENTAL
Intervention: LFD fluconazole prophylaxis (twice a week for up to 6 weeks)
Number of subjects: 244
Study 21040197 — intervention group
Group type: COMPARATOR
Intervention: FD fluconazole prophylaxis (every 72 h for first 2 weeks, every 48 h for next 2 weeks and every 24 h for the final 2 weeks)
Number of subjects: 244
Study 21040197 — intervention group
Group type: EXPERIMENTAL
Intervention: LFD fluconazole prophylaxis
Number of subjects: 244
Study 19403550 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception exercise group (n = 12)
Number of subjects: 24
Study 19403550 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 24
Study 17466699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin administered 15-60 minutes prior to skin incision
Number of subjects: 357
Study 17466699 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin administered at the time of cord clamping
Number of subjects: 357
Study 15478524 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg
Number of subjects: 4
Study 15478524 — intervention group
Group type: COMPARATOR
Intervention: Midodrine 5 mg
Number of subjects: 4
Study 15478524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 11566628 — intervention group
Group type: EXPERIMENTAL
Intervention: MDC and TARC mRNA expression in inflamed mucosa from CD patients
Number of subjects: 0
Study 11566628 — intervention group
Group type: EXPERIMENTAL
Intervention: MDC production from PBMC in CD patients
Number of subjects: 0
Study 11566628 — intervention group
Group type: COMPARATOR
Intervention: MDC and TARC mRNA expression in UC patients
Number of subjects: 0
Study 10021952 — intervention group
Group type: COMPARATOR
Intervention: Epidural F (fentanyl bolus 2 micrograms.kg‐1 in 0.5 ml.kg‐1 saline followed by 2 micrograms.ml‐1 fentanyl infusion)
Number of subjects: 42
Study 10021952 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural F‐B (fentanyl bolus 2 micrograms.kg‐1 in 0.5 ml.kg‐1 bupivacaine 0.25% followed by 2 micrograms.ml‐1 fentanyl infusion in bupivacaine 0.125%)
Number of subjects: 42
Study 7932133 — intervention group
Group type: EXPERIMENTAL
Intervention: STAAR Elastimide three‐piece foldable intraocular lens inserted through a 4.0 mm incision
Number of subjects: 112
Study 7932133 — intervention group
Group type: COMPARATOR
Intervention: STAAR poly(methyl methacrylate) (PMMA) lens inserted through a 7.0 mm incision
Number of subjects: 112
Study 2851506 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens
Number of subjects: 3
Study 2851506 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG OD14
Number of subjects: 3
Study 2851506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 29645341 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg once daily)
Number of subjects: 28
Study 29645341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 28253893 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg orally twice daily
Number of subjects: 200
Study 28253893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 25430779 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg GSK561679 (low-GSK)
Number of subjects: 31
Study 25430779 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg GSK561679 (high-GSK)
Number of subjects: 31
Study 25430779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 31
Study 25430779 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 23701526 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX 380 mg
Number of subjects: 114
Study 20089518 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MBL deficiency (serum MBL levels of or below 100 ng/mL)
Number of subjects: 890
Study 20089518 — intervention group
Group type: COMPARATOR
Intervention: MBL levels >100 ng/mL
Number of subjects: 890
Study 20089518 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MBL deficiency
Number of subjects: 890
Study 18935806 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 0
Study 18935806 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 0
Study 16635636 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-absorbing pylons
Number of subjects: 17
Study 16635636 — intervention group
Group type: COMPARATOR
Intervention: Rigid pylons
Number of subjects: 17
Study 16635636 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Leg
Number of subjects: 17
Study 16635636 — intervention group
Group type: COMPARATOR
Intervention: Mauch SNS knees
Number of subjects: 17
Study 16635636 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekdays activity
Number of subjects: 17
Study 16635636 — intervention group
Group type: EXPERIMENTAL
Intervention: General activity
Number of subjects: 17
Study 14639800 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched eggs (147 mg DHA/egg)
Number of subjects: 153
Study 14639800 — intervention group
Group type: COMPARATOR
Intervention: Ordinary eggs (20 mg DHA/egg)
Number of subjects: 153
Study 14639800 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched eggs (147 mg DHA/egg) in subjects with BMI >= 30 kg/m2
Number of subjects: 153
Study 14639800 — intervention group
Group type: COMPARATOR
Intervention: Ordinary eggs (20 mg DHA/egg) in subjects with BMI >= 30 kg/m2
Number of subjects: 153
Study 10868315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (0.5 mg bid, titrated to a maximum of 6.0 mg tid)
Number of subjects: 24
Study 10868315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of L-dopa and ropinirole
Number of subjects: 24
Study 10868315 — intervention group
Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 24
Study 8989068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (Spfx), 400 mg on day 1, then 200 mg once daily for 10 to 14 days
Number of subjects: 304
Study 8989068 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin (ROXI), 150 mg twice daily for 10 to 14 days
Number of subjects: 304
Study 1456812 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclarubicin in combination with cytarabine (7 + 7)
Number of subjects: 48
Study 1456812 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclarubicin in combination with cytarabine (5 + 5)
Number of subjects: 48
Study 1456812 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclarubicin in combination with cytarabine (7 & 3)
Number of subjects: 48
Study 1456812 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclarubicin in combination with cytarabine (7 + 3)
Number of subjects: 48
Study 3904821 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacle correction of unusually hypermetropic refractions from age 1 year
Number of subjects: 0
Study 31698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.1 mg/day
Number of subjects: 1253
Study 31698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.2 mg/day
Number of subjects: 1253
Study 31698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.4 mg/day
Number of subjects: 1253
Study 31698825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1253
Study 31698825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate (all doses)
Number of subjects: 1253
Study 31698825 — intervention group
Group type: COMPARATOR
Intervention: Pemafibrate and placebo
Number of subjects: 1253
Study 29379953 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended intervention (medication review, 3 motivational interviews, follow-up with primary care physician, pharmacy, and nursing home)
Number of subjects: 1467
Study 29379953 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended intervention
Number of subjects: 1467
Study 29379953 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 1467
Study 29379953 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention (medication review)
Number of subjects: 1467
Study 27301235 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 73
Study 27301235 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 73
Study 27301235 — intervention group
Group type: COMPARATOR
Intervention: Cleansed (Control)
Number of subjects: 73
Study 24818608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 26
Study 24818608 — intervention group
Group type: COMPARATOR
Intervention: Normal-sleep control
Number of subjects: 26
Study 24818608 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressor (Trier Social Stress Test)
Number of subjects: 26
Study 22328287 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIC plus systemic chemotherapy (combined therapy)
Number of subjects: 287
Study 22328287 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy alone (monotherapy)
Number of subjects: 287
Study 20123413 — intervention group
Group type: EXPERIMENTAL
Intervention: Gow-Gates mandibular conduction block anesthesia
Number of subjects: 97
Study 20123413 — intervention group
Group type: EXPERIMENTAL
Intervention: Vazirani-Akinosi inferior alveolar nerve block
Number of subjects: 97
Study 20123413 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal-plus-lingual infiltrations
Number of subjects: 97
Study 20123413 — intervention group
Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block (control)
Number of subjects: 97
Study 17400836 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger
Number of subjects: 0
Study 17400836 — intervention group
Group type: EXPERIMENTAL
Intervention: Shame
Number of subjects: 0
Study 17400836 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilt
Number of subjects: 0
Study 17400836 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of pervasive threat to the country's image
Number of subjects: 0
Study 16082015 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (female soccer players)
Number of subjects: 24
Study 12216602 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative electroacupuncture (EA) for 45 minutes before induction of general anaesthesia (GA)
Number of subjects: 90
Study 12216602 — intervention group
Group type: COMPARATOR
Intervention: Placebo EA for 45 minutes before induction of general anaesthesia (GA)
Number of subjects: 90
Study 12216602 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative electroacupuncture (EA) for 45 minutes
Number of subjects: 90
Study 10707439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg daily for 16 days, then 20 mg for 10 days, continuing for at least 3 months) + Nicotine inhalers (6-12 units/day for up to 6 months)
Number of subjects: 100
Study 10707439 — intervention group
Group type: COMPARATOR
Intervention: Nicotine inhalers (6-12 units/day for up to 6 months) + Placebo (10 mg daily for 16 days, then 20 mg for 10 days, continuing for at least 3 months)
Number of subjects: 100
Study 8942551 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy
Number of subjects: 103
Study 8942551 — intervention group
Group type: COMPARATOR
Intervention: Open biopsy
Number of subjects: 103
Study 8942551 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Satisfaction Survey
Number of subjects: 103
Study 8942551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 103
Study 1763608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium followed by daily oral magnesium tablets
Number of subjects: 58
Study 1763608 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion followed by daily oral placebo tablets
Number of subjects: 58
Study 7077524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7077524 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant
Number of subjects: 32
Study 7077524 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressant
Number of subjects: 32
Study 30096214 — intervention group
Group type: COMPARATOR
Intervention: Anti-CSG video
Number of subjects: 549
Study 30096214 — intervention group
Group type: COMPARATOR
Intervention: Pro-CSG video
Number of subjects: 549
Study 30096214 — intervention group
Group type: COMPARATOR
Intervention: Control group (neutral video)
Number of subjects: 549
Study 29304744 — intervention group
Group type: EXPERIMENTAL
Intervention: High carotenoid diet (375 g/d high carotenoid vegetables, 300 g/d high carotenoid fruit, 40-60 ml extra-virgin olive oil)
Number of subjects: 73
Study 29304744 — intervention group
Group type: COMPARATOR
Intervention: Lower carotenoid diet (375 g/d lower carotenoid vegetables, 300 g/d lower carotenoid fruit, 40-60 ml PUFA based oil)
Number of subjects: 73
Study 27135207 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive couples intervention (n=19)
Number of subjects: 45
Study 27135207 — intervention group
Group type: COMPARATOR
Intervention: Pain programme only (n=26)
Number of subjects: 45
Study 24211192 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up intervention (pre-discharge education and three follow-up calls)
Number of subjects: 124
Study 24211192 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 124
Study 22314015 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based intervention tailored to participant's level of risk of CRC based on self-reported family history assessment.
Number of subjects: 0
Study 22314015 — intervention group
Group type: COMPARATOR
Intervention: Minimal ethical care (Control group).
Number of subjects: 0
Study 19392814 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and sodium valproate
Number of subjects: 88
Study 19392814 — intervention group
Group type: COMPARATOR
Intervention: Sodium valproate
Number of subjects: 88
Study 17986161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol added to transdermal fentanyl (group T)
Number of subjects: 70
Study 17986161 — intervention group
Group type: COMPARATOR
Intervention: Transdermal fentanyl alone (group F)
Number of subjects: 70
Study 15379176 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIONS group (educational intervention for osteoporosis prevention)
Number of subjects: 693
Study 15379176 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 693
Study 11250849 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecure re-employment
Number of subjects: 666
Study 11250849 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployment
Number of subjects: 666
Study 11250849 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent exit from paid employment
Number of subjects: 666
Study 11250849 — intervention group
Group type: COMPARATOR
Intervention: Secure re-employment
Number of subjects: 666
Study 9665954 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of cervical secretions prior to Pap smear using Weck‐cel sponges
Number of subjects: 266
Study 9665954 — intervention group
Group type: COMPARATOR
Intervention: Only Pap smear collection (control group)
Number of subjects: 266